PROTACs for BRDs proteins in cancer therapy: a review

References

• Drummond ML, Williams CI. In silico modeling of PROTAC-mediated ternary complexes: validation and application. J Chem Inf Model 2019;59:1694–44.
   Web of Science ®Google Scholar
• An S, Fu L. Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs. EBioMedicine 2018;36:553–62.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Y, Wang J, et al. VHL-based PROTACs as potential therapeutic agents: recent progress and perspectives. Eur J Med Chem 2022;227:113906.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Y, Wu Y, et al. Developments of CRBN-based PROTACs as potential therapeutic agents. Eur J Med Chem 2021;225:113749.
   PubMed Web of Science ®Google Scholar
• Farnaby W, Koegl M, Roy MJ, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol 2019;15:672–80.
   PubMed Web of Science ®Google Scholar
• Martin-Acosta P, Xiao X. PROTACs to address the challenges facing small molecule inhibitors. Eur J Med Chem 2021;210:112993.
   PubMed Web of Science ®Google Scholar
• Zeng S, Huang W, Zheng X, et al. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges. Eur J Med Chem 2021;210:112981.
   PubMed Web of Science ®Google Scholar
• Smith BE, Wang SL, Jaime-Figueroa S, et al. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat Commun 2019;10:131.
   PubMed Web of Science ®Google Scholar
• Nowak RP, Deangelo SL, Dennis B, et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat Chem Biol 2018;14:706–14.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Y, Xing D, et al. PROTACs technology for targeting non-oncoproteins: advances and perspectives. Bioorg Chem 2021;114:105109.
   PubMed Web of Science ®Google Scholar
• Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov 2017;16:101–14.
   PubMed Web of Science ®Google Scholar
• Gadd MS, Testa A, Lucas X, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol 2017;13:514–21.
   PubMed Web of Science ®Google Scholar
• Roy M, Winkler S, Hughes SJ, et al. SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate. ACS Chem Biol 2019;14:361–8.
   PubMed Web of Science ®Google Scholar
• Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012;6:579–89.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012;149:214–31.
   PubMed Web of Science ®Google Scholar
• Consortium U. Reorganizing the protein space at the universal protein resource (UniProt). Nucleic Acids Res 2012;40:D71–5.
   PubMed Web of Science ®Google Scholar
• Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 2012;12:465–77.
   PubMed Web of Science ®Google Scholar
• Hamm CA, Costa FF. The impact of epigenomics on future drug design and new therapies. Drug Discov Today 2011;16:626–35.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med 2012;367:647–57.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12–27.
   PubMed Web of Science ®Google Scholar
• Habibi E, Masoudi-Nejad A, Abdolmaleky HM, et al. Emerging roles of epigenetic mechanisms in Parkinson’s disease. Funct Integr Genomics 2011;11:523–37.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189–95.
   PubMed Web of Science ®Google Scholar
• Brownlee PM, Chambers AL, Oliver AW, et al. Cancer and the bromodomains of BAF180. Biochem Soc Trans 2012;40:364–9.
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Filippakopoulos P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat Rev Mol Cell Biol 2017;18:246–62.
   PubMed Web of Science ®Google Scholar
• Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov 2018;8:24–36. 201
   PubMed Web of Science ®Google Scholar
• Clark PG, Vieira LC, Tallant C, et al. LP99: discovery and synthesis of the first selective BRD7/9 bromodomain inhibitor. Angew Chem Int Ed Engl 2015;54: 6217–21.
   PubMed Web of Science ®Google Scholar
• Pervaiz M, Mishra P, Günther S. Bromodomain drug discovery - the past, the present, and the future. Chem Rec 2018;18:1808–17.
   PubMed Web of Science ®Google Scholar
• Yang CY, Qin C, Bai L, et al. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review. Drug Discov Today Technol 2019;31:43–51.
   PubMedGoogle Scholar
• Muddassir M, Soni K, Sangani CB, et al. Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs. RSC Adv 2021;11:612–36.
   Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067–73.
   PubMed Web of Science ®Google Scholar
• Shi X, Liu C, Liu B, et al. JQ1: a novel potential therapeutic target. Pharmazie 2018;73:491–3.
   PubMed Web of Science ®Google Scholar
• Leal AS, Williams CR, Royce DB, et al. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Lett 2017;394:76–87.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol 2017;28:1776–87.
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Dowlati A, LoRusso PM, et al. Abstract A49: clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC). Mol Cancer Ther 2015;14:A49–A49.
   Google Scholar
• Bui MH, Lin X, Albert DH, et al. Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies. Cancer Res 2017;77:2976–89.
   PubMed Web of Science ®Google Scholar
• Wang L, Chen Y, Mi Y, et al. ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis. Biochem Biophys Res Commun 2021;558:216–23.
   PubMed Web of Science ®Google Scholar
• Salami J, Crews CM. Waste disposal-An attractive strategy for cancer therapy. Science 2017;355:1163–7.
   PubMed Web of Science ®Google Scholar
• Lu J, Qian Y, Altieri M, et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol 2015;22:755–63.
   PubMedGoogle Scholar
• Winter GE, Buckley DL, Paulk J, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 2015;348:1376–81.
   PubMed Web of Science ®Google Scholar
• Bai L, Zhou B, Yang CY, et al. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res 2017;77:2476–87.
   PubMed Web of Science ®Google Scholar
• Qin C, Hu Y, Zhou B, et al. Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the Bromodomain and Extra-Terminal (BET) proteins capable of inducing complete and durable tumor regression. J Med Chem 2018;61:6685–704.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen P, Zhu P, et al. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative. Bioorg Chem 2020;99:103817.
   PubMed Web of Science ®Google Scholar
• Bemis TA, La Clair JJ, Burkart MD. Traceless Staudinger ligation enabled parallel synthesis of proteolysis targeting chimera linker variants. Chem Commun (Camb) 2021;57:1026–9.
   PubMed Web of Science ®Google Scholar
• Hu R, Wang WL, Yang YY, et al. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor. Eur J Med Chem 2022;227:113922.
   PubMed Web of Science ®Google Scholar
• Min J, Mayasundari A, Keramatnia F, et al. Phenyl-glutarimides: alternative cereblon binders for the design of PROTACs. Angew Chem Int Ed Engl 2021;60:26663–70.
   PubMed Web of Science ®Google Scholar
• Reynders M, Matsuura BS, Bérouti M, et al. PHOTACs enable optical control of protein degradation. Sci Adv 2020;6:eaay5064.
   PubMed Web of Science ®Google Scholar
• Remillard D, Buckley DL, Paulk J, et al. Degradation of the BAF complex factor BRD9 by heterobifunctional ligands. Angew Chem Int Ed Engl 2017;56:5738–43.
   PubMed Web of Science ®Google Scholar
• Goracci L, Desantis J, Valeri A, et al. Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications. J Med Chem 2020;63:11615–38.
   PubMed Web of Science ®Google Scholar
• Ohoka N, Ujikawa O, Shimokawa K, et al. Different degradation mechanisms of inhibitor of apoptosis proteins (IAPs) by the specific and nongenetic IAP-dependent protein eraser (SNIPER). Chem Pharm Bull (Tokyo) 2019;67:203–9.
   PubMed Web of Science ®Google Scholar
• Zengerle M, Chan KH, Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem Biol 2015;10:1770–7.
   PubMed Web of Science ®Google Scholar
• Kounde CS, Shchepinova MM, Saunders CN, et al. A caged E3 ligase ligand for PROTAC-mediated protein degradation with light. Chem Commun (Camb) 2020;56:5532–5.
   PubMed Web of Science ®Google Scholar
• He S, Gao F, Ma J, et al. Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer. Angew Chem Int Ed Engl 2021;60:23299–305.
   PubMed Web of Science ®Google Scholar
• Wyce A, Degenhardt Y, Bai Y, et al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget 2013;4:2419–29.
   PubMed Web of Science ®Google Scholar
• Raina K, Lu J, Qian Y, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci USA 2016;113:7124–9.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen H, Liu Y, et al. Cancer selective target degradation by folate-caged PROTACs. J Am Chem Soc 2021;143:7380–7.
   PubMed Web of Science ®Google Scholar
• Pfaff P, Samarasinghe KTG, Crews CM, et al. Reversible spatiotemporal control of induced protein degradation by bistable photoPROTACs. ACS Cent Sci 2019;5:1682–90.
   PubMed Web of Science ®Google Scholar
• Zoppi V, Hughes SJ, Maniaci C, et al. Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel-Lindau (vhl) based dual degrader probe of BRD9 and BRD7. J Med Chem 2019;62:699–726.
   PubMed Web of Science ®Google Scholar
• Hugle M, Lucas X, Ostrovskyi D, et al. Beyond the BET family: targeting CBP/p300 with 4-acyl pyrroles. Angew Chem Int Ed Engl 2017;56:12476–80.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhen XT, Denton E, et al. ChromoHub: a data hub for navigators of chromatin-mediated signalling. Bioinformatics 2012;28:2205–6.
   PubMed Web of Science ®Google Scholar